Publications Follow us as we translate our deep expertise in structure-based drug discovery into novel, selective therapeutics that enable durable responses for patients with cancer. Publications All ROS1 NSCLC ALK NSCLC HER2ex20 Load More Patient Impact Drives Solutions Your browser does not support the video tag. James R. Porter, PhD Chief Executive Officer Jim shares more about Nuvalent’s foundation and approach – to provide new impactful therapies for patients living with cancer.
